In a groundbreaking move, the United States Food and Drug Administration has recently given its nod to two pioneering cell-based gene therapies, Casgevy and
Montana's SB422 'Right to Try' bill allows access to experimental treatments, expanding medical autonomy and setting a precedent for healthcare innovation.